Global Hospital Acquired Infections Market - 2023-2030

Global Hospital Acquired Infections Market - 2023-2030

The Global Hospital Acquired Infections Market reached US$ 14.4 billion in 2022 and is projected to witness lucrative growth by reaching up to US$ 19.5 billion by 2030. The global hospital acquired infections market is expected to exhibit a CAGR of 3.8% during the forecast period 2023-2030. The increasing hospital admissions and the growing clinical trials for novel drugs are driving up demand for hospital acquired infections market trends.

When a patient receives medication at a healthcare center or from a doctor, they may contract hospital-acquired infections, also known as healthcare-associated infections. The patient's lungs, skin, blood, digestive or urinary tracts could all get infected. Sepsis, surgical site infections, catheter-associated urinary tract infections and others are examples of healthcare-associated infections. Drugs that are antiviral or antibacterial are used to treat these illnesses.

The hospital acquired infections market scope comprises drug type as antibacterial drugs, antiviral drugs, antifungal drugs and others, which has increased the hospital acquired infections market share. The global market for hospital acquired infections is expanding as a result of factors including increasing research and development and their upcoming medical approvals across countries are also creating a positive outlook for the hospital acquired infections market growth.

Market Dynamics

An Increase in the Incidence of Hospital Acquired Infections Drive the Growth of the Hospital Acquired Infections Market

According to the Centers for Disease Control (CDC), HAIs are expected to cause 1.7 million illnesses and 99,000 deaths annually in American hospitals alone. Of these illnesses, urinary tract infections account for 32% of all healthcare-acquired infections, surgical site infections for 22%, pneumonia (lung infections) for 15% and bloodstream infections for 14%.

Additionally, the Public Health Agency of Canada predicted in August 2022 that 2% of patients admitted to major academic hospitals in Canada will contract an infection during their stay and that 3% to 10% of hospitalized patients will at any given time be infected with or carrying an antimicrobial-resistant organism. Hence, the growing hospital acquired infection is driving the hospital acquired infections market.

Rising Awareness and Research and Development Creates Lucrative Opportunities for Manufacturers

High mortality and morbidity rates from healthcare-associated infections cost the healthcare industry billions of dollars annually. Many guidelines for monitoring, setting up and tracking central lines and isolating infected patients have been created throughout the years. The only way to make a difference is for all healthcare teams to work together. Preventing the spread of infectious agents amongst patients and medical personnel is the main tactic used in hospitals.

Since they frequently come into contact with infected patients initially, nurses are essential to prevention. The key to preventing infections is hand washing and ensuring that everyone abides by the stated guidelines. Numerous category 1A recommendations, such as securing catheters, teaching medical staff about infection control practices, hand washing and the use of aseptic techniques during invasive procedures. Thus these factors will create opportunities for the growth of hospital acquired infections market size.

Stringent Pricing of Drugs will Hamper the Growth of the Market.

Drug pricing is a difficult process that involves numerous players and greatly affects cost-effectiveness. Pricing based on value is a technique for figuring out the cost-effective price for the medicine.

Although it is not yet clear how value-based pricing will affect the costs of new antibacterial drugs, a key determining factor will be the notion of value, which may include not only the effect of the drug on the patient's health but also its wider impact on society and the health effects of the disease. Hence these above-mentioned factors are limiting the hospital-acquired infections market’s growth.

COVID-19 Impact Analysis

The financial health of companies across all industries has been impacted by the COVID-19 pandemic and lockdown in numerous nations throughout the world. Therefore, for the period of the COVID-19 public health emergency, the U.S. Food and Drug Administration (FDA) issued guidelines that include general considerations to aid sponsors and researchers, ensuring the safety of trial participants, adhering to good clinical practice (GCP) and minimizing risks to trial integrity.

Russia-Ukraine War Impact Analysis

The Russia-Ukraine conflict is estimated to have a moderate impact on the global hospital-acquired infections market, owing to the low number of key market players in this region. However, the impact of the import and export of raw materials is expected to have little influence over the global hospital acquired infections market growth over the forecast period.

Segment Analysis

The global hospital acquired infections market is segmented based on infection type, drug type, end user and region.

Antibacterial drugs from the Drug Type Segment Account for 37.3% of the Market Share Owing to Rising Novel Product Launches

Antibacterial medications, also referred to as antibiotics, are a class of pharmaceuticals used to treat bacterial infections. Antibiotics focus on specific bacteria or bacterial processes, like protein synthesis or cell wall construction. The nature and extent of the ailment will determine the exact treatment and dosage. Antibacterial medications can be administered intravenously, topically, or orally, among other ways.

Recently, many new antimicrobial drugs with new targets have hit the market, albeit others are still awaiting FDA approval. Macrocyclic antibiotics, more recent cephalosporins, glycopeptides, carbapenems, pleuromutilin and other ones are a few of them. Today, one of the antibiotic classes most frequently recommended for the treatment of bacterial infections is lactams. By blocking PBPs, which are necessary for cross-linking in cell wall production, they prevent bacterial growth.

Geographical Analysis

North America Accounted for Approximately 38.4% of the Market Share Owing to the Strong Presence of Major Players and Increasing Technological Advancements

Manufacturers have chances to expand their operations in this region because of the rising demand for hospital-acquired infections for advancements in North America. The area has many producers and suppliers and its rapid economic development has raised industrial production of hospital-acquired infections, which has increased the demand.

North America has a large number of producers and suppliers, and as a result of the swift economic development of the area, industrial production has increased, fueling the demand for hospital acquired infections.

Rising new drug or infection types will drive market growth. Growth is also fueled by rising technological advancements, regulatory approvals and novel product launches. Researchers are becoming more aware of various kinds of diagnostic approaches for infectious disorders, leading to the expansion of the market in this region. These factors show the dominance of North America.

Competitive Landscape

The major global players in the hospital acquired infections market include F Hoffmann-la Roche Ltd, Pfizer Inc., AbbVie Inc., AstraZeneca, GSK plc, Innoviva, Eli Lilly and Company, Steris, Cipla Inc. and Basilea Pharmaceutica Ltd. among others.

Why Purchase the Report?
• To visualize the global hospital-acquired infections market segmentation based on infection type, drug type, end user and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of hospital-acquired infections market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The Global Hospital Acquired Infections Market Report Would Provide Approximately 53 Tables, 54 Figures and 195 Pages.

Target Audience 2023
• Manufacturers / Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies